Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 7/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469945 | 1.00 | PDK2 (0.46) | PDK2NOS3NOS1NOS2NAPRT | |
| Potassium SCHEMBL29930626 | 0.98 | PDK2 (0.45) | PDK2NOS3NOS1NOS2NAPRT | |
| SCHEMBL28763152 | 0.92 | NOS3 (0.42) | PDK2NOS3NOS1NOS2NAPRT | |
| SCHEMBL5954915 | 0.92 | NOS1 (0.42) | PDK2NOS3NOS1NOS2NAPRT | |
| SCHEMBL2718434 | 0.90 | CYP11B2 (0.43) | PDK2NOS3NOS1NOS2HTR1A | |
| SCHEMBL624461 | 0.89 | DHFR (0.42) | PDK2NOS3NOS1NOS2NAPRT | |
| SCHEMBL1693643 | 0.87 | PDE10A (0.42) | — | |
| SCHEMBL1429509 | 0.87 | HTR1A (0.55) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17477141 | 0.84 | HTR1D (0.43) | NOS3NOS1NOS2HTR1ACYP1A2 | |
| SCHEMBL24364886 | 0.82 | NOS3 (0.41) | PDK2NOS3NOS1NOS2NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143007-A | Tetrahydrocarbazole derivative and photocatalytic synthesis method thereof | 陕西科技大学 | 2023-12-01 | — | — | CN | claimed |
| EP-4737450-A1 | HETEROAROMATIC FORMAMIDE COMPOUNDS AND USES THEREOF IN MEDICINE | Longwood Pharmaceuticals (Hangzhou) Co., Ltd (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-101048406-B | Novel substituted imidazole derivatives | BANYU PHARMA CO LTD | 2010-12-22 | — | — | CN | disclosed |
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-2114942-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| CN-101573361-A | Novel aminopyrimidine derivative as plk1 inhibitor | BANYU PHARMA CO LTD (JP) | 2009-11-04 | — | — | CN | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2008081910-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-10 | — | — | WO | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| CN-101048406-A | Novel substituted imidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-10-03 | — | — | CN | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | PDK2 1179/4885NOS3 1709/4885NOS1 2598/4885 |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | PDK2 2529/4885NOS3 1702/4885NOS1 1392/4885 |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | PDK2 441/4885NOS3 3049/4885NOS1 3161/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | PDK2 3411/4885NOS3 4868/4885NOS1 4754/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | PDK2 2529/4885NOS3 1702/4885NOS1 1392/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | PDK2 3411/4885NOS3 4868/4885NOS1 4754/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | PDK2 2276/4885NOS3 556/4885NOS1 619/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | PDK2 2276/4885NOS3 556/4885NOS1 619/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | PDK2 4119/4885NOS3 2054/4885NOS1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.